Trevi Therapeutics (NASDAQ:TRVI – Get Free Report) posted its quarterly earnings results on Tuesday. The company reported ($0.11) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.01, Zacks reports.
Trevi Therapeutics Trading Up 0.8 %
Trevi Therapeutics stock traded up $0.06 during mid-day trading on Tuesday, hitting $6.60. The company had a trading volume of 2,202,888 shares, compared to its average volume of 968,847. The company has a market capitalization of $506.93 million, a price-to-earnings ratio of -14.99 and a beta of 0.90. Trevi Therapeutics has a 12-month low of $2.30 and a 12-month high of $7.39. The company’s fifty day moving average is $4.39 and its 200-day moving average is $3.66.
Insider Activity
In related news, insider Farrell Simon sold 81,313 shares of the firm’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $6.75, for a total transaction of $548,862.75. Following the sale, the insider now owns 76,900 shares in the company, valued at approximately $519,075. This trade represents a 51.39 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 24.37% of the company’s stock.
Wall Street Analyst Weigh In
Get Our Latest Stock Report on Trevi Therapeutics
Trevi Therapeutics Company Profile
Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.
Recommended Stories
- Five stocks we like better than Trevi Therapeutics
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- How to Invest in Small Cap Stocks
- 3 Must-Own Stocks to Build Wealth This Decade
- Stock Dividend Cuts Happen Are You Ready?
- Advanced Micro Devices Eyes AI Market Growth—Is AMD a Buy?
Receive News & Ratings for Trevi Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevi Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.